HPN217 is intended for the treatment of relapsed/refractory multiple myeloma. Credit: aslysun/Shutterstock.com.

Harpoon Therapeutics has completed the planned enrolment of patients in the Phase I clinical trial of HPN217 for the treatment of relapsed/refractory multiple myeloma.

The trial intends to enrol additional patients who are currently in screening.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The dose escalation, open-label, multicentre study will assess the pharmacokinetics (PK), tolerability, safety, and clinical activity of HPN217 that targets the B-cell maturation antigen (BCMA).

Patients with relapsed/refractory multiple myeloma who previously received at least three systemic treatments, including an anti-CD38 antibody, an immunomodulatory drug, and a proteasome inhibitor, are enrolled in the study.

In addition, patients previously exposed to BCMA therapy are included in the study.

See Also:

Characterisation of PK, tolerability, safety, and determining the recommended Phase II dose are the primary objectives of the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Harpoon Therapeutics president and CEO Julie Eastland said: “We are pleased to have achieved this important milestone for Harpoon, with the enrolment of the first of our two Tri-specific T cell Activating Construct (TriTAC) clinical compounds having completed dose escalation as planned.

“The identification of the recommended dose(s) for Phase II and the presentation of Phase I data is anticipated by the end of 2023.”

Harpoon is also developing a pipeline of TriTACs compounds for treating haematologic malignancies and solid tumours.

AbbVie can exercise its option to license HPN217 after completion of the Phase I study, as per the licensing agreement signed between the company and Harpoon in November 2019.